Beta-thalassemia major (β-TM) is a severe hereditary haemoglobinopathy that is rarely associated with hematological malignancies. Though isolated case reports of association with acute lymphoblastic leukemia, acute myeloid leukemia is known. Only a few case reports of the association of β-TM and chronic myeloid leukemia (CML) are known. We present a case of a 25-year-old male with β-TM who later developed CML. The patient's management involved a multidisciplinary approach, incorporating hematological, molecular, and genetic assessments. This report indicates that malignancies should be suspected and kept in mind in patients with β-thalassemia syndromes presenting with proposed signs and symptoms including unexplained lymphadenopathy, leukocytosis, and splenomegaly. This case highlights the importance of comprehensive evaluation and tailored therapeutic strategies in complex hematological disorders.

Keywords: Chronic Myeloid Leukemia (CML); Beta Thalassemia

References

1. Alavi S., et al. “Hematological malignancies complicating β-thalassemia syndromes: a single center experience”. Blood Research2 (2013): 149.
2. Alabdulaali M., et al. “Chronic myelogenous leukemia in sickle cell/beta 0 -thalassemia”. Indian Journal of Pathology and Microbiology3 (2011): 597.
3. Monni G., et al. “From Prenatal to Preimplantation Genetic Diagnosis of β-Thalassemia. Prevention Model in 8748 Cases: 40 Years of Single Center Experience”. Journal of Clinical Medicine2 (2018): 35.
4. Asnafi AA., et al. “Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches”. Journal of Cell Physiology5 (2019): 5798-5806.
5. Hochhaus A., et al. “European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia”. Leukemia4 (2020): 966-984.
6. Hoffmann VS., et al. “The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries”. Leukemia 6 (2015): 1336-1343.
7. Yadav SS., et al. “Prevalence and Management of β-Thalassemia in India”. Hemoglobin 1 (2022): 27-32.
8. Pellegrino C., et al. “Acute Promyelocytic Leukemia in a Woman with Thalassemia Intermedia: Case Report and Review of Literature on Hematological Malignancies in β-Thalassemia Patients”. Hematology Report 4 (2022): 310-321.
9. Kim HJ., et al. “Coexistence of chronic myeloid leukemia and pulmonary plasmacytoma mimicking primary lung cancer”. International Journal of Hematology4 (2010): 651-654.
10. Vachhani NA., et al. “Spectrum of β-Thalassemia and Other Hemoglobinopathies in the Saurashtra Region of Gujarat, India: Analysis of a Large Population Screening Program”. Hemoglobin5 (2022): 285-289.
11. Sarnaik SA. “Thalassemia and related hemoglobinopathies”. The Indian Journal of Pediatrics4 (2005): 319-324.
12. BENETATOS L., et al. “Malignancies in β ‐thalassemia patients: a single‐center experience and a concise review of the literature”. International Journal of Laboratory Hematology 2 (2008): 167-172.
13. Cao A and Galanello R. “Beta-thalassemia”. Genetics in Medicine2 (2010): 61-76.
14. Russo A and Schiirò G. “Letter to the editor: Thalassemia major and malignancies”. American Journal of Hematology1 (1987): 111-111.
15. Karimi M., et al. “Malignancies in patients with β‐thalassemia major and β‐thalassemia intermedia: A multicenter study in Iran”. Pediatric Blood Cancer6 (2009): 1064-1067.
16. Telfer P. “Update on Survival in Thalassemia Major”. Hemoglobin 33 (2009): S76-80.
17. Druker BJ., et al. “Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia”. New England Journal of Medicine23 (2006): 2408-2417.

Citation

Citation: Gurpreet Kaur., et al. “Beta Thalassemia Major and Chronic Myeloid Leukemia in a Young Adult Male: A Rare Combination”.Acta Scientific Cancer Biology 8.5 (2024): 04-07.

Copyright

Copyright: © 2024 Gurpreet Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.